Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies

Neurobiology of Disease

Volumn 109, Issue , 2018, Pages 209-218

  Peng, Chao ^a   Gathagan, Ronald J ^a   Lee, Virginia M Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dementia with Lewy body; Multiple system atrophy; Parkinson's disease; Protein aggregates; Synuclein strains; Synucleinopathy

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PROTEIN;

ALZHEIMER DISEASE; BETA SHEET; BRAIN REGION; CELLULAR DISTRIBUTION; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; EXOCYTOSIS; HUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MISFOLDING; REVIEW; SHY DRAGER SYNDROME; ANIMAL; CHEMISTRY; DEGENERATIVE DISEASE; GENETICS; METABOLISM; PROTEIN CONFORMATION; PROTEINOSIS;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN CONFORMATION;

EID: 85026252066     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2017.07.018     Document Type: Review

References (167)

1. Aarsland, D., et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60 (2003), 387–392.
2. Abeliovich, A., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000), 239–252.
3. Aguzzi, A., et al. Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell. Biol. 8 (2007), 552–561.
4. Ahmed, Z., et al. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol. Appl. Neurobiol. 38 (2012), 4–24.
5. Apaydin, H., et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59 (2002), 102–112.
6. Appel-Cresswell, S., et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28 (2013), 811–813.
7. Asi, Y.T., et al. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 62 (2014), 964–970.
8. Association, A.P., Association, A.P., DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Text Revision. 2000, American Psychiatric Association, Washington, DC, 75.
9. Avila, J., et al. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84 (2004), 361–384.
10. Barker, R.A., Williams-Gray, C.H., Review: the spectrum of clinical features seen with alpha synuclein pathology. Neuropathol. Appl. Neurobiol. 42 (2016), 6–19.
11. Bartels, T., et al. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477 (2011), 107–110.
12. Ben-Shlomo, Y., et al. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 48 (1997), 384–393.
13. Bernis, M.E., et al. Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol. Commun., 3, 2015, 75.
14. Bertoncini, C.W., et al. Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. J. Biol. Chem. 280 (2005), 30649–30652.
15. Boelle, P.Y., et al. Epidemiological evidence of higher susceptibility to vCJD in the young. BMC Infect. Dis., 4, 2004, 26.
16. Boluda, S., et al. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. Acta Neuropathol. 129 (2015), 221–237.
17. Bousset, L., et al. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun., 4, 2013, 2575.
18. Bower, J.H., et al. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49 (1997), 1284–1288.
19. Braak, H., Del Tredici, K., The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 121 (2011), 171–181.
20. Braak, H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003), 197–211.
21. Braak, H., et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64 (2005), 1404–1410.
22. Brown, K., Mastrianni, J.A., The prion diseases. J. Geriatr. Psychiatry Neurol. 23 (2010), 277–298.
23. Burre, J., The synaptic function of alpha-synuclein. J. Park. Dis. 5 (2015), 699–713.
24. Burre, J., et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329 (2010), 1663–1667.
25. Cabin, D.E., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22 (2002), 8797–8807.
26. Chandra, S., et al. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123 (2005), 383–396.
27. Clavaguera, F., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11 (2009), 909–913.
28. Clavaguera, F., et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 9535–9540.
29. Cohen, M.L., et al. Rapidly progressive Alzheimer's disease features distinct structures of amyloid-beta. Brain 138 (2015), 1009–1022.
30. Collinge, J., Molecular neurology of prion disease. J. Neurol. Neurosurg. Psychiatry 76 (2005), 906–919.
31. Collinge, J., et al. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383 (1996), 685–690.
32. Compta, Y., et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 134 (2011), 1493–1505.
33. Dauer, W., et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 14524–14529.
34. Davidson, W.S., et al. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273 (1998), 9443–9449.
35. Del Tredici, K., et al. Where does Parkinson disease pathology begin in the brain?. J. Neuropathol. Exp. Neurol. 61 (2002), 413–426.
36. DeWitt, D.C., Rhoades, E., alpha-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers. Biochemistry 52 (2013), 2385–2387.
37. Dickson, D.W., Brown, P., Multiple prion types in the same brain: is a molecular diagnosis of CJD possible?. Neurology 53 (1999), 1903–1904.
38. Dickson, D.W., et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 8 (2009), 1150–1157.
39. Duara, R., et al. A comparison of familial and sporadic Alzheimer's disease. Neurology 43 (1993), 1377–1384.
40. Esiri, M.M., et al. The Neuropathology of Dementia. 2004, Cambridge University Press.
41. Fanciulli, A., Wenning, G.K., Multiple-system atrophy. N. Engl. J. Med. 372 (2015), 1375–1376.
42. Fernandez-Chacon, R., et al. The synaptic vesicle protein CSP alpha prevents presynaptic degeneration. Neuron 42 (2004), 237–251.
43. Fortin, D.L., et al. Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24 (2004), 6715–6723.
44. Fraser, H., Dickinson, A.G., Scrapie in mice. Agent-strain differences in the distribution and intensity of grey matter vacuolation. J. Comp. Pathol. 83 (1973), 29–40.
45. Frost, B., et al. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284 (2009), 12845–12852.
46. Fuchs, J., et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68 (2007), 916–922.
47. Fujioka, S., et al. Update on novel familial forms of Parkinson's disease and multiple system atrophy. Parkinsonism Relat. Disord. 20:Suppl. 1 (2014), S29–34.
48. Gajdusek, D.C., Zigas, V., Degenerative disease of the central nervous system in New Guinea; the endemic occurrence of kuru in the native population. N. Engl. J. Med. 257 (1957), 974–978.
49. Gambetti, P., et al. Sporadic and familial CJD: classification and characterisation. Br. Med. Bull. 66 (2003), 213–239.
50. Gearing, M., et al. Neurofibrillary pathology in Alzheimer disease with Lewy bodies: two subgroups. Arch. Neurol. 56 (1999), 203–208.
51. Geschwind, M.D., Prion diseases. Continuum (Minneap Minn). 21 (2015), 1612–1638.
52. Giasson, B.I., et al. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276 (2001), 2380–2386.
53. Gilman, S., et al. The North American multiple system atrophy study group. J. Neural. Transm. (Vienna) 112 (2005), 1687–1694.
54. Gilman, S., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71 (2008), 670–676.
55. Golbe, L.I., et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann. Neurol. 40 (1996), 767–775.
56. Gomez-Tortosa, E., et al. Clinical and neuropathological correlates of dementia with Lewy bodies. Ann. N. Y. Acad. Sci. 920 (2000), 9–15.
57. Greten-Harrison, B., et al. alphabetagamma-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 19573–19578.
58. Guo, J.L., Lee, V.M., Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 286 (2011), 15317–15331.
59. Guo, J.L., et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154 (2013), 103–117.
60. Halliday, G.M., et al. Striatal beta-amyloid in dementia with Lewy bodies but not Parkinson's disease. J. Neural. Transm. (Vienna) 118 (2011), 713–719.
61. Hamilton, R.L., Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 10 (2000), 378–384.
62. Heath, C.A., et al. Diagnosing variant Creutzfeldt–Jakob disease: a retrospective analysis of the first 150 cases in the UK. J. Neurol. Neurosurg. Psychiatry 82 (2011), 646–651.
63. Heilbronner, G., et al. Seeded strain-like transmission of beta-amyloid morphotypes in APP transgenic mice. EMBO Rep. 14 (2013), 1017–1022.
64. Hely, M.A., et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23 (2008), 837–844.
65. Iba, M., et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33 (2013), 1024–1037.
66. Ikeda, K., et al. Clinical aspects of argyrophilic grain disease. Clin. Neuropathol. 19 (2000), 278–284.
67. Irwin, D.J., et al. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 135 (2012), 807–818.
68. Irwin, D.J., et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72 (2012), 587–598.
69. Irwin, D.J., et al. Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat. Rev. Neurosci. 14 (2013), 626–636.
70. Jellinger, K.A., Dementia with grains (argyrophilic grain disease). Brain Pathol. 8 (1998), 377–386.
71. Jellinger, K.A., Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J. Neural Transm. Suppl., 2007, 91–104.
72. Jellinger, K.A., Attems, J., Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?. Acta Neuropathol. 112 (2006), 253–260.
73. Jellinger, K.A., Attems, J., Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 115 (2008), 427–436.
74. Jellinger, K.A., et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J. Neural. Transm. (Vienna) 109 (2002), 329–339.
75. Jellinger, K.A., et al. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov. Disord. 20:Suppl. 12 (2005), S29–36.
76. Jensen, P.H., et al. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273 (1998), 26292–26294.
77. Jensen, M.B., et al. Membrane curvature sensing by amphipathic helices: a single liposome study using alpha-synuclein and annexin B12. J. Biol. Chem. 286 (2011), 42603–42614.
78. Johnson, R.T., Gibbs, C.J. Jr., Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N. Engl. J. Med. 339 (1998), 1994–2004.
79. Kahle, P.J., et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20 (2000), 6365–6373.
80. Kempster, P.A., et al. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 133 (2010), 1755–1762.
81. Kiely, A.P., et al. alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol. 125 (2013), 753–769.
82. Kim, H.J., et al. Survival of Korean patients with multiple system atrophy. Mov. Disord. 26 (2011), 909–912.
83. Kim, W.S., et al. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res. Ther., 6, 2014, 73.
84. Kim, C., et al. Exposure to bacterial endotoxin generates a distinct strain of alpha-synuclein fibril. Sci Rep, 6, 2016, 30891.
85. Kollensperger, M., et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov. Disord. 25 (2010), 2604–2612.
86. Kordower, J.H., et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14 (2008), 504–506.
87. Kotzbauer, P.T., et al. Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch. Neurol. 69 (2012), 1326–1331.
88. Kovari, E., et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol. 106 (2003), 83–88.
89. Kraybill, M.L., et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64 (2005), 2069–2073.
90. Kruger, R., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998), 106–108.
91. Kruger, R., et al. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 56 (2001), 1355–1362.
92. Lasagna-Reeves, C.A., et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep, 2, 2012, 700.
93. Lashley, T., et al. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 115 (2008), 417–425.
94. Lee, V.M., et al. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001), 1121–1159.
95. Lesage, S., et al. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73 (2013), 459–471.
96. Levy, G., et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann. Neurol. 51 (2002), 722–729.
97. Lewis, S.J., et al. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J. Neurol. Neurosurg. Psychiatry 76 (2005), 343–348.
98. Li, J.Y., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14 (2008), 501–503.
99. Liberski, P.P., et al. Kuru: the first prion disease. Adv. Exp. Med. Biol. 724 (2012), 143–153.
100. Lippa, C.F., et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68 (2007), 812–819.
101. Litvan, I., et al. Phenotypes and prognosis: clinicopathologic studies of corticobasal degeneration. Adv. Neurol. 82 (2000), 183–196.
102. Lu, J.X., et al. Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154 (2013), 1257–1268.
103. Luk, K.C., et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 20051–20056.
104. Luk, K.C., et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 (2012), 949–953.
105. Luk, K.C., et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 209 (2012), 975–986.
106. Manix, M., et al. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg. Focus., 39, 2015, E2.
107. Markesbery, W.R., et al. Lewy body pathology in normal elderly subjects. J. Neuropathol. Exp. Neurol. 68 (2009), 816–822.
108. Maroteaux, L., Scheller, R.H., The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res. Mol. Brain Res. 11 (1991), 335–343.
109. Masuda-Suzukake, M., et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 136 (2013), 1128–1138.
110. Matsuoka, Y., et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8 (2001), 535–539.
111. Mattila, P.M., et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. 100 (2000), 285–290.
112. McCann, H., et al. alpha-Synucleinopathy phenotypes. Parkinsonism Relat. Disord. 20:Suppl. 1 (2014), S62–7.
113. Mead, S., Prion disease genetics. Eur. J. Hum. Genet. 14 (2006), 273–281.
114. Meyer-Luehmann, M., et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313 (2006), 1781–1784.
115. Mikolaenko, I., et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J. Neuropathol. Exp. Neurol. 64 (2005), 156–162.
116. Miller, D.W., et al. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J. Neural. Transm. (Vienna) 112 (2005), 1613–1624.
117. Mullan, M., et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1 (1992), 345–347.
118. Munch, C., et al. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 3548–3553.
119. Murphy, D.D., et al. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20 (2000), 3214–3220.
120. Nekooki-Machida, Y., et al. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 9679–9684.
121. Nishioka, K., et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 59 (2006), 298–309.
122. Nonaka, T., et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4 (2013), 124–134.
123. Pattison, I.H., Millson, G.C., Scrapie produced experimentally in goats with special reference to the clinical syndrome. J. Comp. Pathol. 71 (1961), 101–109.
124. Paumier, K.L., et al. Intrastriatal injection of pre-formed mouse alpha-synuclein fibrils into rats triggers alpha-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol. Dis. 82 (2015), 185–199.
125. Peelaerts, W., et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522 (2015), 340–344.
126. Petkova, A.T., et al. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307 (2005), 262–265.
127. Pineda, A., Burre, J., Modulating membrane binding of alpha-synuclein as a therapeutic strategy. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), 1223–1225.
128. Polymenidou, M., et al. Coexistence of multiple PrPSc types in individuals with Creutzfeldt–Jakob disease. Lancet Neurol. 4 (2005), 805–814.
129. Polymeropoulos, M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2047.
130. Postuma, R.B., et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 30 (2015), 1591–1601.
131. Proukakis, C., et al. A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80 (2013), 1062–1064.
132. Prusiner, S.B., et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E5308–17.
133. Puoti, G., et al. Sporadic Creutzfeldt-Jakob disease: co-occurrence of different types of PrP(Sc) in the same brain. Neurology 53 (1999), 2173–2176.
134. Querfurth, H.W., LaFerla, F.M., Alzheimer's disease. N. Engl. J. Med. 362 (2010), 329–344.
135. Ren, P.H., et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 11 (2009), 219–225.
136. Richardson, J.C., et al. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of “heterogenous system degeneration”. Trans. Am. Neurol. Assoc. 88 (1963), 25–29.
137. Rochet, J.C., et al. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 23 (2004), 23–34.
138. Rudge, P., et al. Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain 138 (2015), 3386–3399.
139. Ryan, N.S., Rossor, M.N., Correlating familial Alzheimer's disease gene mutations with clinical phenotype. Biomark. Med 4 (2010), 99–112.
140. Sabbagh, M.N., et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis. Assoc. Disord. 23 (2009), 295–297.
141. Sacino, A.N., et al. Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 10732–10737.
142. Sanders, D.W., et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82 (2014), 1271–1288.
143. Schenkein, J., Montagna, P., Self-management of fatal familial insomnia. Part 2: case report. MedGenMed., 8, 2006, 66.
144. Schiesling, C., et al. Review: familial Parkinson's disease—genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol. Appl. Neurobiol. 34 (2008), 255–271.
145. Selikhova, M., et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 132 (2009), 2947–2957.
146. Stohr, J., et al. Purified and synthetic Alzheimer's amyloid beta (Abeta) prions. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 11025–11030.
147. Tanaka, M., et al. Conformational variations in an infectious protein determine prion strain differences. Nature 428 (2004), 323–328.
148. Taniguchi-Watanabe, S., et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 131 (2016), 267–280.
149. Telling, G.C., et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274 (1996), 2079–2082.
150. Tsigelny, I.F., et al. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J. 274 (2007), 1862–1877.
151. Tsuboi, Y., et al. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat. Disord. 13:Suppl. 3 (2007), S221–4.
152. Tu, P.H., et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 44 (1998), 415–422.
153. Ueda, K., et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 11282–11286.
154. Volles, M.J., et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001), 7812–7819.
155. Volpicelli-Daley, L.A., et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72 (2011), 57–71.
156. Watanabe, H., et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125 (2002), 1070–1083.
157. Watts, J.C., et al. Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 19555–19560.
158. Watts, J.C., et al. Serial propagation of distinct strains of Abeta prions from Alzheimer's disease patients. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 10323–10328.
159. Weinreb, P.H., et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (1996), 13709–13715.
160. Woerman, A.L., et al. Propagation of prions causing synucleinopathies in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E4949–58.
161. Woerman, A.L., et al. Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E8187–E8196.
162. Yavich, L., et al. Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci. 24 (2004), 11165–11170.
163. Yavich, L., et al. Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice. J. Neurochem. 99 (2006), 724–732.
164. Yoshida, M., Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 27 (2007), 484–493.
165. Yull, H.M., et al. Detection of type 1 prion protein in variant Creutzfeldt–Jakob disease. Am. J. Pathol. 168 (2006), 151–157.
166. Zarranz, J.J., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004), 164–173.
167. Zharikov, A.D., et al. shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model. J. Clin. Invest. 125 (2015), 2721–2735.